Director, Commercial Strategy & New Product Planning

Remote Position Summary The Director, Commercial Strategy & New Product Planning will lead and support a wide range of strategic and operational initiatives across MBX's portfolio. This individual will help shape commercialization strategy for canvuparatide while also helping define the future direction of our obesity and metabolic disease pipeline. The ideal candidate combines strong analytical and strategic capabilities with a willingness to roll up their sleeves and execute. This role is well suited for individuals coming from biopharmaceutical marketing, commercial strategy, business analytics, or leading life sciences consulting firms who are excited to build, influence decisions, and grow alongside an emerging organization. Key Responsibilities Help define long-term commercial strategy across MBX's portfolio Evaluate market opportunities, competitive dynamics, and evolving standards of care Support portfolio prioritization and investment decisions Develop commercial assessments for new indications, lifecycle opportunities, and business development initiatives Partner closely with R&D and clinical teams to ensure commercial considerations are incorporated into development plans Launch Preparation & Commercial Readiness Support launch planning and commercialization activities for canvuparatide Identify key market opportunities, barriers to adoption, and launch risks Develop launch assumptions and readiness plans across key functional areas Help establish foundational commercial capabilities and processes as MBX prepares for commercialization Lead market research initiatives with physicians, patients, payers, and other stakeholders Translate market insights into actionable strategic recommendations Monitor competitive developments and emerging market trends Develop deep understanding of customer needs, treatment journeys, and market dynamics Support development of product positioning, value propositions, and messaging frameworks Contribute to brand strategy and commercialization planning Develop and refine Target Product Profiles (TPPs) and commercial product profiles Assess differentiation opportunities and competitive positioning across the portfolio Forecasting & Analytics Support development and refinement of demand forecasts and commercial models Evaluate market sizing, patient flow, and adoption assumptions Develop strategic analyses to inform investment decisions and resource allocation Prepare presentations and recommendations for executive leadership and board discussions Cross‑Functional Leadership Partner closely with Clinical Development, Medical Affairs, Regulatory, Market Access, Finance, Investor Relations, and Business Development Lead cross‑functional projects and strategic workstreams Manage external agencies, consultants, and research partners as needed Serve as a key commercial representative on cross‑functional teams Education & Qualifications Bachelor's degree required; advanced degree preferred (MBA, MPH, PharmD, PhD, or related field) 8+ years of relevant experience in biotechnology, pharmaceuticals, healthcare consulting, or related fields Experience in commercial strategy, marketing, new product planning, forecasting, market research, analytics, or consulting Strong analytical, strategic thinking, and problem‑solving skills Excellent communication and presentation abilities Ability to operate effectively in a fast‑paced, entrepreneurial environment Travel & Location You will be expected to travel periodically, based on business needs, including attending Together Weeks, Together Days, and functional meetings as requested by the Company. This role is expected to be on‑site an average of three days per week, unless otherwise requested. Company Overview MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company's pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism preparing for Phase 3 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development and MBX 5765 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the Company website at and follow it on LinkedIn. EEO Statement MBX Biosciences is an Equal Opportunity Employer and is committed to treating all applicants fairly without discrimination. We welcome applications from all individuals, regardless of race, national origin, gender, age, physical characteristics, social origin, disability, union membership, religion, family status, pregnancy, sexual orientation, gender identity, gender expression or any unlawful criterion under applicable law. #J-18808-Ljbffr MBX Biosciences, Inc.